So as we know that there’s been a huge initiative to get increased representation into clinical trials, all the clinical trials that have failed up until this far, up until this point, have recognized the lack of diversity. So even the ones that have failed or even the ones that have been pushed through, we can’t, in essence, say that a therapy, a diagnostic, anything that is thought to improve, have any improved clinical benefit for a diverse population, if it wasn’t tested, if it wasn’t investigated in that diverse population, there’s still a gap in knowledge that we need to fill...
So as we know that there’s been a huge initiative to get increased representation into clinical trials, all the clinical trials that have failed up until this far, up until this point, have recognized the lack of diversity. So even the ones that have failed or even the ones that have been pushed through, we can’t, in essence, say that a therapy, a diagnostic, anything that is thought to improve, have any improved clinical benefit for a diverse population, if it wasn’t tested, if it wasn’t investigated in that diverse population, there’s still a gap in knowledge that we need to fill. And so there have been some studies that have seen differences that different racial and ethnic groups do respond differently, do require different treatment strategies. So in order for us to be able to truly develop therapies, diagnostics that are going to be applicable for all, we have to be able to address those questions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
